Fluocinolone Acetonide
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Fluocinolone Acetonide: Lichen planus pemphigoides
One-Sentence Summary
Fluocinolone acetonide is a synthetic corticosteroid used in skin preparations for inflammatory and itchy skin conditions. The TxGNN model predicts it may be effective for lichen planus pemphigoides, but no clinical trials and no publications were found to support this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Lichen planus pemphigoides |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data show that fluocinolone acetonide acts on the glucocorticoid receptor (NR3C1), the target through which corticosteroids suppress inflammation and immune activity.
Lichen planus pemphigoides combines features of lichen planus with subepidermal autoimmune blistering similar to pemphigoid. Corticosteroids are a mainstay of immunosuppressive treatment in pemphigoid-spectrum disease, which gives a plausible mechanistic link. However, management of this disease is often systemic rather than topical-only, so a topical product may not be sufficient for all patients. Route compatibility and similarity to the drug’s existing uses have not yet been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02300559 | DERMOTIC OIL EAR DROPS | Not stated | Not stated |
| 00873292 | DERMA SMOOTHE/FS LIQ 0.01% | Not stated | Not stated |
| 02459655 | OTIXAL | Not stated | Not stated |
All three licences are currently valid.
Safety Considerations
- Drug Interactions: An interaction screen returned 9 drug pairs, all with an unclassified severity level: dexamethasone, cetirizine, citalopram, valproic acid, acetaminophen, digoxin, levothyroxine, alendronic acid and clonazepam. The clinical significance of each has not been graded.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support for this prediction is a high model score (0.9934). There are no registered trials or publications on lichen planus pemphigoides, so the evidence level is L5. The corticosteroid mechanism is plausible, but it is not enough on its own to justify moving forward.
To proceed, the following is needed:
- A systematic literature search for case reports or studies of corticosteroids in lichen planus pemphigoides
- Health Canada package insert warnings and contraindications
- Detailed mechanism of action data
- Assessment of whether topical routes are adequate, given that disease management is often systemic
- Review of the drug interaction findings with graded severity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.